Literature DB >> 15551055

Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body.

T Kuorilehto1, M Pöyhönen, R Bloigu, J Heikkinen, K Väänänen, Juha Peltonen.   

Abstract

Neurofibromatosis type 1 (NF1) is a dominantly inherited disease. Skeletal ailments such as short stature, kyphoscoliosis, tibial bowing and pseudarthrosis are common osseous manifestations of NF1. Previously, a correlation with scoliosis and decreased bone mineral density (BMD) of the lumbar spine has been reported in 12 NF1 patients. A total of 35 NF1 patients and 26 healthy controls were included in the present study. Of the participants over 20 years of age (26 NF1 patients and all controls) 14 were male and 12 were female, seven of whom were premenopausal. The controls were matched for age, sex and body mass index (BMI). Physical activity and medical history of NF1 patients were evaluated to screen the fractures and osseous manifestations of the disease and to rule out the factors that effect BMD. BMD and bone mineral content (BMC) were measured with DXA, using a total body program. The present study detected a lowered bone mineral density (p =0.028) and content (p <0.001) in NF1 patients of both sexes. The results of the present study also show that NF1 patients have an increased risk for osteoporosis. Among NF1 patients seven cases of osteoporosis and 13 cases of osteopenia were detected. In controls, one case of osteoporosis and 13 cases of osteopenia were detected. The location of the lowest local BMD was clustered to the load-carrying parts of the body in NF1 patients. Physical activity and the medical history of the NF1 patients did not explain the decreased BMD and BMC. The findings of the present and previous studies suggest that the pathogenesis of the osseous manifestations in NF1 may involve impaired development of the skeletal system and impaired maintenance of bone structure.

Entities:  

Mesh:

Year:  2004        PMID: 15551055     DOI: 10.1007/s00198-004-1801-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  21 in total

1.  Abnormal development of the lesser wing of the sphenoid with microphthalmos and microcephaly.

Authors:  C Jacquemin; P Mullaney; T M Bosley
Journal:  Neuroradiology       Date:  2001-02       Impact factor: 2.804

2.  Relative contribution of lean and fat mass component to bone mineral density in males.

Authors:  Tsutomu Douchi; Riki Kuwahata; Takashi Matsuo; Hirofumi Uto; Toshimichi Oki; Yukihiro Nagata
Journal:  J Bone Miner Metab       Date:  2003       Impact factor: 2.626

Review 3.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

Review 4.  Neurofibromatosis 1: clinical manifestations and diagnostic criteria.

Authors:  J M Friedman
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

5.  A clinical assessment of neurofibromatosis type 1 (NF1) and segmental NF in Northern Finland.

Authors:  M Poyhonen
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

6.  The diagnosis of osteoporosis.

Authors:  J A Kanis; L J Melton; C Christiansen; C C Johnston; N Khaltaev
Journal:  J Bone Miner Res       Date:  1994-08       Impact factor: 6.741

7.  The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes.

Authors:  M M Daston; H Scrable; M Nordlund; A K Sturbaum; L M Nissen; N Ratner
Journal:  Neuron       Date:  1992-03       Impact factor: 17.173

8.  Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients.

Authors:  J M Friedman; P H Birch
Journal:  Am J Med Genet       Date:  1997-05-16

9.  cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product.

Authors:  D A Marchuk; A M Saulino; R Tavakkol; M Swaroop; M R Wallace; L B Andersen; A L Mitchell; D H Gutmann; M Boguski; F S Collins
Journal:  Genomics       Date:  1991-12       Impact factor: 5.736

10.  Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA).

Authors:  Rachel I Gafni; Jeffrey Baron
Journal:  J Pediatr       Date:  2004-02       Impact factor: 4.406

View more
  46 in total

1.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

2.  Activating transcription factor 4 regulates osteoclast differentiation in mice.

Authors:  Huiling Cao; Shibing Yu; Zhi Yao; Deborah L Galson; Yu Jiang; Xiaoyan Zhang; Jie Fan; Binfeng Lu; Youfei Guan; Min Luo; Yumei Lai; Yibei Zhu; Noriyoshi Kurihara; Kenneth Patrene; G David Roodman; Guozhi Xiao
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

3.  Bone resorption in syndromes of the Ras/MAPK pathway.

Authors:  D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali
Journal:  Clin Genet       Date:  2011-01-19       Impact factor: 4.438

4.  ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae.

Authors:  Florent Elefteriou; M Douglas Benson; Hideaki Sowa; Michael Starbuck; Xiuyun Liu; David Ron; Luis F Parada; Gerard Karsenty
Journal:  Cell Metab       Date:  2006-12       Impact factor: 27.287

5.  Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.

Authors:  Feng-Chun Yang; Shi Chen; Alexander G Robling; Xijie Yu; Todd D Nebesio; Jincheng Yan; Trent Morgan; Xiaohong Li; Jin Yuan; Janet Hock; David A Ingram; D Wade Clapp
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

6.  Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Authors:  Steven D Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl W Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S Mohammad; Theresa A Guise; Mingjiang Xu; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

7.  Effects of resveratrol on the proliferation and osteogenic differentiation of deciduous dental pulp stem cells from neurofibromatosis type 1 patient.

Authors:  Claudinéia Pereira Maranduba; Gustavo Torres Souza; Antônio Márcio Resende do Carmo; José Marcelo Sallabert de Campos; Nádia Rezende Barbosa Raposo; Marcelo de Olivera Santos; Carlos Magno da Costa Maranduba; Fernando de Sá Silva
Journal:  Childs Nerv Syst       Date:  2020-11-20       Impact factor: 1.475

Review 8.  Gastrointestinal and retroperitoneal manifestations of type 1 neurofibromatosis.

Authors:  Ursula Basile; Giuseppe Cavallaro; Andrea Polistena; Sandra Giustini; Gennaro Orlando; Dario Cotesta; Luigi Petramala; Claudio Letizia; Stefano Calvieri; Giorgio De Toma
Journal:  J Gastrointest Surg       Date:  2010-01       Impact factor: 3.452

9.  Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Authors:  Steven D Rhodes; Xiaohua Wu; Yongzheng He; Shi Chen; Hao Yang; Karl W Staser; Jiapeng Wang; Ping Zhang; Chang Jiang; Hiroki Yokota; Ruizhi Dong; Xianghong Peng; Xianlin Yang; Sreemala Murthy; Mohamad Azhar; Khalid S Mohammad; Mingjiang Xu; Theresa A Guise; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

10.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.

Authors:  Richa Sharma; Xiaohua Wu; Steven D Rhodes; Shi Chen; Yongzheng He; Jin Yuan; Jiliang Li; Xianlin Yang; Xiaohong Li; Li Jiang; Edward T Kim; David A Stevenson; David Viskochil; Mingjiang Xu; Feng-Chun Yang
Journal:  Hum Mol Genet       Date:  2013-07-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.